It may have taken an order from the Federal Trade Commission to get there—and Medtronic may be getting less bang for its buck than initially expected—but the medtech giant’s acquisition of Intersect ...

MENLO PARK, Calif., Apr 17, 2012 (BUSINESS WIRE) -- Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and patients, today announced that the company is ...

What: Shares of Intersect ENT,a drug-device company focusing on developing therapeutic solutions for patients with ear, nose, and throat conditions, dropped by more than 26% today on exceptional ...

MENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it has ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the appointment of ...

Medtronic's proposed acquisition of Intersect ENT raised some eyebrows at the Federal Trade Commission. The FTC ordered Medtronic to divest Intersect's Fiagon business within 10 days of the ...

Staying true to its pledge to crack down on potentially anticompetitive megamergers in the healthcare industry, the U.S. Federal Trade Commission has ordered Medtronic and Intersect ENT to adjust the ...